Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: Systematic review and network meta-analyses

George C. Roush, Theodore R. Holford, Achuta K. Guddati

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Hydrochlorothiazide (HCTZ) is widely used for hypertension, and prescriptions for HCTZ outnumber those for chlorthalidone (CTDN) by >20-fold in 2 recent surveys. Some have recently expressed a preference for CTDN. However, head-to-head trials testing the effect of the 2 drugs on cardiovascular events (CVEs) are lacking. We conducted a systematic review of randomized trials in which 1 arm was based on either HCTZ or CTDN followed by 2 types of network meta-analyses, a drug-adjusted analysis and an office systolic blood pressure-adjusted analysis. Nine trials were identified: 3 based on HCTZ and 6 based on CTDN. In the drug-adjusted analysis (n=50946), the percentage of risk reduction in congestive heart failure for CTDN versus HCTZ was 23 (95% CI, 2-39; P=0.032); and in all CVEs was 21 (95% CI, 12-28; P<0.0001). In the office systolic blood pressure-adjusted analysis (n=78350), the percentage of risk reduction in CVEs for CTDN versus HCTZ was 18 (95% CI, 3-30; P=0.024). When the reduction in office systolic blood pressure was identical in the 2 arms, the risk for CVEs in HCTZ arms was 19% higher than in its nondiuretic comparator arms (P=0.021). Relative to HCTZ, the number needed to treat with CTDN to prevent 1 CVE over 5 years was 27. In conclusion, CTDN is superior to HCTZ in preventing cardiovascular events. This cannot be attributed entirely to the lesser effect of HCTZ on office systolic blood pressure but may be attributed to the pleomorphic effects of alternative medications or to the short duration of action of HCTZ.

Original languageEnglish (US)
Pages (from-to)1110-1117
Number of pages8
JournalHypertension
Volume59
Issue number6
DOIs
StatePublished - Jun 1 2012

Fingerprint

Chlorthalidone
Hydrochlorothiazide
Blood Pressure
Risk Reduction Behavior
Network Meta-Analysis
Cardiovascular Agents
Numbers Needed To Treat
Pharmaceutical Preparations
Prescriptions

Keywords

  • Cardiovascular diseases
  • Chlorthalidone/therapeutic use
  • Hydrochlorothiazide/therapeutic use
  • Hypertension
  • Meta-analysis
  • Randomized controlled trials

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events : Systematic review and network meta-analyses. / Roush, George C.; Holford, Theodore R.; Guddati, Achuta K.

In: Hypertension, Vol. 59, No. 6, 01.06.2012, p. 1110-1117.

Research output: Contribution to journalArticle

@article{028a7987397f4f56b70e9d424a125dfb,
title = "Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: Systematic review and network meta-analyses",
abstract = "Hydrochlorothiazide (HCTZ) is widely used for hypertension, and prescriptions for HCTZ outnumber those for chlorthalidone (CTDN) by >20-fold in 2 recent surveys. Some have recently expressed a preference for CTDN. However, head-to-head trials testing the effect of the 2 drugs on cardiovascular events (CVEs) are lacking. We conducted a systematic review of randomized trials in which 1 arm was based on either HCTZ or CTDN followed by 2 types of network meta-analyses, a drug-adjusted analysis and an office systolic blood pressure-adjusted analysis. Nine trials were identified: 3 based on HCTZ and 6 based on CTDN. In the drug-adjusted analysis (n=50946), the percentage of risk reduction in congestive heart failure for CTDN versus HCTZ was 23 (95{\%} CI, 2-39; P=0.032); and in all CVEs was 21 (95{\%} CI, 12-28; P<0.0001). In the office systolic blood pressure-adjusted analysis (n=78350), the percentage of risk reduction in CVEs for CTDN versus HCTZ was 18 (95{\%} CI, 3-30; P=0.024). When the reduction in office systolic blood pressure was identical in the 2 arms, the risk for CVEs in HCTZ arms was 19{\%} higher than in its nondiuretic comparator arms (P=0.021). Relative to HCTZ, the number needed to treat with CTDN to prevent 1 CVE over 5 years was 27. In conclusion, CTDN is superior to HCTZ in preventing cardiovascular events. This cannot be attributed entirely to the lesser effect of HCTZ on office systolic blood pressure but may be attributed to the pleomorphic effects of alternative medications or to the short duration of action of HCTZ.",
keywords = "Cardiovascular diseases, Chlorthalidone/therapeutic use, Hydrochlorothiazide/therapeutic use, Hypertension, Meta-analysis, Randomized controlled trials",
author = "Roush, {George C.} and Holford, {Theodore R.} and Guddati, {Achuta K.}",
year = "2012",
month = "6",
day = "1",
doi = "10.1161/HYPERTENSIONAHA.112.191106",
language = "English (US)",
volume = "59",
pages = "1110--1117",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events

T2 - Systematic review and network meta-analyses

AU - Roush, George C.

AU - Holford, Theodore R.

AU - Guddati, Achuta K.

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Hydrochlorothiazide (HCTZ) is widely used for hypertension, and prescriptions for HCTZ outnumber those for chlorthalidone (CTDN) by >20-fold in 2 recent surveys. Some have recently expressed a preference for CTDN. However, head-to-head trials testing the effect of the 2 drugs on cardiovascular events (CVEs) are lacking. We conducted a systematic review of randomized trials in which 1 arm was based on either HCTZ or CTDN followed by 2 types of network meta-analyses, a drug-adjusted analysis and an office systolic blood pressure-adjusted analysis. Nine trials were identified: 3 based on HCTZ and 6 based on CTDN. In the drug-adjusted analysis (n=50946), the percentage of risk reduction in congestive heart failure for CTDN versus HCTZ was 23 (95% CI, 2-39; P=0.032); and in all CVEs was 21 (95% CI, 12-28; P<0.0001). In the office systolic blood pressure-adjusted analysis (n=78350), the percentage of risk reduction in CVEs for CTDN versus HCTZ was 18 (95% CI, 3-30; P=0.024). When the reduction in office systolic blood pressure was identical in the 2 arms, the risk for CVEs in HCTZ arms was 19% higher than in its nondiuretic comparator arms (P=0.021). Relative to HCTZ, the number needed to treat with CTDN to prevent 1 CVE over 5 years was 27. In conclusion, CTDN is superior to HCTZ in preventing cardiovascular events. This cannot be attributed entirely to the lesser effect of HCTZ on office systolic blood pressure but may be attributed to the pleomorphic effects of alternative medications or to the short duration of action of HCTZ.

AB - Hydrochlorothiazide (HCTZ) is widely used for hypertension, and prescriptions for HCTZ outnumber those for chlorthalidone (CTDN) by >20-fold in 2 recent surveys. Some have recently expressed a preference for CTDN. However, head-to-head trials testing the effect of the 2 drugs on cardiovascular events (CVEs) are lacking. We conducted a systematic review of randomized trials in which 1 arm was based on either HCTZ or CTDN followed by 2 types of network meta-analyses, a drug-adjusted analysis and an office systolic blood pressure-adjusted analysis. Nine trials were identified: 3 based on HCTZ and 6 based on CTDN. In the drug-adjusted analysis (n=50946), the percentage of risk reduction in congestive heart failure for CTDN versus HCTZ was 23 (95% CI, 2-39; P=0.032); and in all CVEs was 21 (95% CI, 12-28; P<0.0001). In the office systolic blood pressure-adjusted analysis (n=78350), the percentage of risk reduction in CVEs for CTDN versus HCTZ was 18 (95% CI, 3-30; P=0.024). When the reduction in office systolic blood pressure was identical in the 2 arms, the risk for CVEs in HCTZ arms was 19% higher than in its nondiuretic comparator arms (P=0.021). Relative to HCTZ, the number needed to treat with CTDN to prevent 1 CVE over 5 years was 27. In conclusion, CTDN is superior to HCTZ in preventing cardiovascular events. This cannot be attributed entirely to the lesser effect of HCTZ on office systolic blood pressure but may be attributed to the pleomorphic effects of alternative medications or to the short duration of action of HCTZ.

KW - Cardiovascular diseases

KW - Chlorthalidone/therapeutic use

KW - Hydrochlorothiazide/therapeutic use

KW - Hypertension

KW - Meta-analysis

KW - Randomized controlled trials

UR - http://www.scopus.com/inward/record.url?scp=84861531899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861531899&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.112.191106

DO - 10.1161/HYPERTENSIONAHA.112.191106

M3 - Article

C2 - 22526259

AN - SCOPUS:84861531899

VL - 59

SP - 1110

EP - 1117

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 6

ER -